Royal Marsden Nhs Foundation Trust
Clinical trials sponsored by Royal Marsden Nhs Foundation Trust, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug duo aims to outsmart stubborn cancers Results expected Sep 2026 (estimated)
- Melanoma survivors: could immunotherapy harm your heart years later? Results expected Sep 2026 (estimated)
- Scientists probe cancer's secret evolution after radiation Results expected Oct 2026 (estimated)
- Blood test may guide cancer care without biopsy Results expected Dec 2026 (estimated)
- Could less radiation be better for prostate cancer? Results expected Jan 2027 (estimated)
-
Immune booster added to standard cervical cancer treatment shows promise in early trial
Disease control Stopped earlyThis study tested adding the immune-boosting drug pembrolizumab to standard chemoradiation for people with advanced cervical cancer. The goal was to see if the combination is safe and to find the best dose. Only one person was enrolled before the study was stopped early, so resul…
Phase 1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Radiation boosts immunotherapy in melanoma? small trial halted early
Disease control Stopped earlyThis phase II trial tested whether adding radiotherapy to the immunotherapy drug pembrolizumab could better control advanced melanoma than pembrolizumab alone. Only 17 people took part before the study was stopped early. The goal was to see if radiation could trigger an 'abscopal…
Phase 2 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Immunotherapy combo tested for tough head and neck cancers
Disease control Stopped earlyThis early-phase trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemoradiation is safe for people with stage IV head and neck cancer. Only 3 patients were enrolled before the study was stopped. The main goal was to find the highest safe do…
Phase 1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Experimental combo for rare lung cancer shows early promise but trial halted
Disease control Stopped earlyThis early-phase trial tested the drug pembrolizumab (Keytruda) combined with targeted radiation (SBRT) in 5 people with advanced malignant pleural mesothelioma, a rare cancer of the lung lining. The goal was to check safety and find the right dose. The study was terminated early…
Phase 1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Experimental combo for advanced lung cancer shows early promise but trial halted
Disease control Stopped earlyThis early-phase trial tested the combination of the immunotherapy drug pembrolizumab (Keytruda) with precise, high-dose radiation (SBRT) in patients with advanced non-small cell lung cancer that had progressed after chemotherapy. The study aimed to find the safest radiation dose…
Phase 1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC